company background image
IMGO

Imago BioSciencesNasdaqGS:IMGO Stock Report

Last Price

US$17.84

Market Cap

US$598.2m

7D

-10.6%

1Y

n/a

Updated

21 Jan, 2022

Data

Company Financials +
IMGO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMGO Stock Overview

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow.

Price History & Performance

Summary of all time highs, changes and price drops for Imago BioSciences
Historical stock prices
Current Share PriceUS$17.84
52 Week HighUS$35.68
52 Week LowUS$14.61
Beta0
1 Month Change-22.94%
3 Month Change-31.93%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO9.52%

Recent News & Updates

Dec 08
We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

IMGOUS BiotechsUS Market
7D-10.6%-5.2%-4.0%
1Yn/a-20.0%6.6%

Return vs Industry: Insufficient data to determine how IMGO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IMGO performed against the US Market.

Price Volatility

Is IMGO's price volatile compared to industry and market?
IMGO volatility
IMGO Average Weekly Movement14.8%
Biotechs Industry Average Movement10.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: IMGO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: IMGO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201220Hugh Rienhoffhttps://www.imagobio.com

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Imago BioSciences Fundamentals Summary

How do Imago BioSciences's earnings and revenue compare to its market cap?
IMGO fundamental statistics
Market CapUS$598.15m
Earnings (TTM)-US$33.13m
Revenue (TTM)n/a

0.0x

P/S Ratio

-18.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMGO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$33.14m
Earnings-US$33.13m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did IMGO perform over the long term?

See historical performance and comparison

Valuation

Is Imago BioSciences undervalued compared to its fair value and its price relative to the market?

2.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMGO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMGO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMGO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMGO is overvalued based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2x).


Future Growth

How is Imago BioSciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

1.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMGO is forecast to have no revenue next year.

High Growth Revenue: IMGO is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMGO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Imago BioSciences performed over the past 5 years?

-105.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: IMGO is currently unprofitable.

Growing Profit Margin: IMGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IMGO's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare IMGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: IMGO has a negative Return on Equity (-14.51%), as it is currently unprofitable.


Financial Health

How is Imago BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: IMGO's short term assets ($234.6M) exceed its short term liabilities ($8.9M).

Long Term Liabilities: IMGO has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IMGO is debt free.

Reducing Debt: IMGO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMGO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMGO has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 54.2% each year.


Dividend

What is Imago BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average management tenure


CEO

Hugh Rienhoff (68 yo)

9.83yrs

Tenure

US$732,628

Compensation

Dr. Hugh Young Rienhoff, Jr., M.D., serves as Chairman of the Board at Parvus Therapeutics Inc. since July 16, 2019. Dr. Rienhoff serves as a Managing Director of Life Science Venture Partners. Dr. Rienhof...


CEO Compensation Analysis

Compensation vs Market: Hugh's total compensation ($USD732.63K) is below average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Insufficient data to compare Hugh's compensation with company performance.


Leadership Team

Experienced Management: IMGO's management team is seasoned and experienced (9.8 years average tenure).


Board Members

Experienced Board: IMGO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: IMGO only recently listed within the past 12 months.


Top Shareholders

Company Information

Imago BioSciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Imago BioSciences, Inc.
  • Ticker: IMGO
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$598.152m
  • Shares outstanding: 33.53m
  • Website: https://www.imagobio.com

Number of Employees


Location

  • Imago BioSciences, Inc.
  • 329 Oyster Point Boulevard
  • 3rd Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 00:12
End of Day Share Price2022/01/20 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.